1. Executive Summary & Investment Thesis

Acadia Healthcare Company, Inc. (NASDAQ: ACHC), headquartered in Franklin, Tennessee, is the largest pure-play provider of behavioral healthcare and psychiatric services in the United States. Founded in 2005, Acadia operates a nationwide network of approximately 260 behavioral healthcare facilities encompassing over 11,400 licensed beds across 40 states and Puerto Rico. Under Chief Executive Officer Chris Hunter (former Humana executive appointed in 2022), the company operates across three specialized care categories:

1. Acute Inpatient Psychiatric Facilities: Standalone psychiatric hospitals providing intensive, 24-hour therapeutic and psychiatric crisis stabilization for children, adolescents, and adults suffering from severe psychiatric disorders (bipolar, schizophrenia, acute suicidal ideation). This segment constitutes over 50% of beds and operational revenue.
2. Specialty Treatment Facilities & Residential Treatment Centers (RTCs): Longer-term residential care programs, eating disorder facilities (e.g., Timberline Knolls), and adolescent behavioral programs providing specialized multi-month interventions.
3. Comprehensive Treatment Centers (CTCs) / Medication-Assisted Treatment (MAT): Outpatient addiction recovery clinics dispensing methadone and buprenorphine alongside counseling for opioid use disorder (OUD), operating over 160 locations across the country.

flowchart TD
    subgraph AcadiaEnterpriseArchitecture["Acadia Healthcare Enterprise Footprint (~11,400 Beds | $3.4B Revenue)"]
        direction TB
        ACUTE["<b>Acute Inpatient Psychiatric Hospitals (~50%+ Rev)</b><br/>Crisis Stabilization | Inpatient Suicide/Psychosis Care<br/>Certificate of Need (CON) Protected Beds"]
        RTC["<b>Specialty Treatment & Residential Centers</b><br/>Eating Disorders | Adolescent RTCs | Trauma Centers<br/>Timberline Knolls | Private Payer & Medicaid"]
        CTC["<b>Comprehensive Treatment Centers (MAT)</b><br/>160+ Outpatient Clinics | Opioid Addiction Recovery<br/>Daily Methadone & Buprenorphine Dispensation"]

        OVERHEAD["<b>Structural Debt Overhead & Compliance Strain</b><br/>$2.41B Funded Debt ($2.24B Net Debt) | BB- Credit Rating<br/>$140M-$150M Annual Cash Interest Burden"]

        CRISIS["<b>Forensic & Regulatory Crisis</b><br/>$996.2M Goodwill Impairment (Q4 2025)<br/>DOJ & SEC Subpoenas (Involuntary Hold Scandal)<br/>$179M Securities Class Action Settlement"]
    end

    ACUTE & RTC & CTC --> OVERHEAD
    OVERHEAD --> CRISIS
    CRISIS -.->|"Gate K3 & K4 Disqualification"| VERDICT["<b>ValueMark Verdict: AVOID</b><br/>MOS: -12.0% | Klarman Floor: $15.00<br/>Quality Score: 31/100 (Failed Gate K3)"]

However, when audited under our 15-Philosopher ValueMark Framework, Acadia Healthcare fails two mandatory Knockout Quality Gates and represents an archetypal healthcare value trap:

1. Failure of Knockout Gate K3 (Balance Sheet Distress & Excessive Leverage): Acadia carries $2.41 billion in funded debt** against **$171.3 million in cash, yielding **$2.24 billion in net debt**. Compared to normalized Adjusted EBITDA of ~$590M–$615M, Net Debt / EBITDA stands at **3.7x–3.8x** (and on a reported GAAP basis with FY25 net losses of -$1.10B, leverage is severely impaired). S&P maintains a BB- rating with a Negative Outlook, warning that elevated legal settlements, PLGL reserves, and debt servicing strain liquidity.
2. Failure of Knockout Gate K4 (Forensic Accounting & Regulatory Integrity):
   • The Involuntary Patient Hold Scandal: In September 2024, the New York Times published an explosive exposé revealing that Acadia systematically held behavioral patients against their will under emergency involuntary hold laws (e.g., Florida Baker Act), falsifying psychiatric symptoms to trap patients until their commercial insurance or Medicaid benefits were fully exhausted.
   • DOJ & SEC Subpoenas: The investigative reporting triggered federal Department of Justice (DOJ) subpoenas, an active SEC investigation, and inquiries by the Department of Veterans Affairs and HHS Office of Inspector General (OIG).
   • Goodwill Impairment & Loss of Payer Access: In Q4 2025, Acadia wrote down $996.2 million in goodwill, reflecting impaired future earnings power following New York State Department of Health’s decision to ban Medicaid referrals to Acadia facilities in Pennsylvania.
   • Cash Flow Destruction: Driven by massive, debt-fueled facility construction ($690.4M capex in 2024 and$571.8M in 2025), cumulative Owner Free Cash Flow from 2021 through 2025 totaled a staggering -$916.6 million.

Triangulating through-the-cycle intrinsic fair value at $26.75 per share** establishes a **negative Margin of Safety of -12.0$29.96, while trading 99.7% above our Seth Klarman Bear Floor ($15.00). Disqualified by Gate K3 and forensic peril, Acadia commands a Master Value Score of 31 / 100 and an authoritative AVOID verdict.

---

A. Core Thesis Pillars & Two-Minute Monologue (Peter Lynch)

• Stock Archetype: Turnaround (a distressed healthcare facility roll-up facing systemic regulatory probes, a massive debt load, and damaged clinical reputation).
• The Two-Minute Drill: “Acadia Healthcare operates in an industry with undeniable secular tailwinds: America faces an acute mental health and addiction crisis, and inpatient psychiatric beds are structurally undersupplied due to state Certificate of Need laws. On the surface, Acadia looks like a classic value opportunity: revenue compounds at 9.4% to $3.4 billion, and the stock has fallen from its historical peak of$85+ down to $29.96. But value investors following Benjamin Graham, Terry Smith, and Seth Klarman must look past headline revenue growth to examine the quality of the profit engine. Acadia’s past growth was fueled by relentless debt and aggressive admission practices that crossed ethical and legal boundaries. The company is now under federal investigation by the Department of Justice and SEC for holding patients involuntarily to drain their insurance policies. New York has already banned Medicaid referrals to its Pennsylvania facilities, and the company took a massive$996 million goodwill write-down in 2025, posting a $1.1 billion net loss. Furthermore, with$2.24 billion in net debt and leverage exceeding 3.7x EBITDA, Acadia strictly fails Knockout Gate K3. Over the past five years, the company burned nearly $1 billion in cumulative Owner Free Cash Flow due to aggressive bed expansion. Even if operations stabilize, normalized fair value is only$26.75, and if federal prosecutors extract punitive damages or exclude facilities from Medicare, the stock easily drops to its $15.00 Klarman Bear Floor. Acadia is a dangerous value trap. We strictly avoid.”
• Runway & Destination: While physical psychiatric bed capacity will remain necessary, Acadia’s future organic expansion will be strictly constrained. Management has been forced to slash annual capital expenditures by over $300 million to divert cash toward debt servicing and legal liabilities. Payer scrutiny will permanently cap admission lengths of stay and compress operating margins.

---

B. The Klarman Test: Why Is It Cheap? (Source of Mispricing / Value Trap Anatomy)

Under Seth Klarman’s Margin of Safety methodology (Rule 05), we analyze why the market prices ACHC at $29.96 and expose the behavioral traps ensnaring investors:

1. The Optic “Low Multiple” Fallacy on Non-GAAP EBITDA: Retail investors and sell-side analysts frequently value Acadia at ~8x management’s “Adjusted EBITDA” guidance ($600M), arguing the stock is heavily discounted relative to peers like Universal Health Services (UHS). However, Adjusted EBITDA aggressively adds back essential operating expenses: professional liability litigation costs ($40M+ annually), legal defense fees for DOJ probes, and stock-based compensation ($32M). On genuine GAAP earnings and Owner Cash Flow, the enterprise trades at an exorbitant multiple.
2. Underestimating Federal Exclusion Risk: The market treats the DOJ and SEC inquiries as mere routine litigation that will end with a manageable civil fine. But for a healthcare facility operator, the threat of exclusion from CMS (Medicare/Medicaid) or mandatory Corporate Integrity Agreements (CIAs) poses catastrophic existential risk. Government payers account for over 50% of patient days.
3. The Capital Expenditure Treadmill: Unlike software or asset-light franchises, psychiatric hospitals require continuous physical maintenance to meet stringent life-safety codes (ligature-resistant fixtures, security monitoring, nurse staffing ratios). Cumulative 5-year CapEx of $2.23B completely consumed cumulative Operating Cash Flow ($1.48B), forcing Acadia to issue debt to fund its existence.

---

C. Catalysts & Value-Realization Path (Workout Timeline)

1. Resolution of DOJ / SEC Subpoenas: Potential global civil settlement with federal authorities establishing monetary damages and compliance mandates (expected 2027).
2. CapEx Rationalization: Transition from aggressive greenfield construction to cash-flow preservation, aiming to generate $200M+ in annual free cash flow for debt paydown.
3. Payer Contract Renegotiations: Stabilizing commercial reimbursement rates and rebuilding relationships with state Medicaid agencies to restore referred patient volumes.

---

2. Economic Moat, SES & Competitive Durability

• Moat Rating: Narrow (Trend: Narrowing)
• Primary Moat Sources: State Certificate of Need (CON) Regulations, Acute Hospital Joint-Venture Integration, High Clinical Switching Costs.

flowchart LR
    subgraph MoatAudit["Acadia Healthcare Moat Evaluation (Rule 07, Pillar 2)"]
        direction TB
        M1["CON Regulatory Shield: <b>MODERATE</b> (Artificial Supply Barrier in ~35 States)"]
        M2["Switching Costs: <b>WEAKENING</b> (Referral Sources Diversifying Away from ACHC)"]
        M3["Gross Margin Shield: <b>COMPRESSED</b> (Staffing Shortages & PLGL Litigation Costs)"]
        M4["Scale Economics Shared: <b>ABSENT</b> (Scale Retained to Cover Debt & Overhead)"]
        M5["Spawner DNA: <b>FAILED</b> (Past UK Divestiture & Debt-Laden Acquisition History)"]
    end

A. Certificate of Need (CON) Laws as an Artificial Supply Shield

Acadia’s sole durable competitive advantage is derived from state regulatory protection. Approximately 35 U.S. states enforce Certificate of Need (CON) statutes for behavioral healthcare, which legally prohibit the construction of new psychiatric facilities unless an applicant proves that existing regional beds are inadequate.

• High Local Monopoly Power: In CON states, existing licensed facilities operate as local monopolies or duopolies. Competitors cannot simply purchase real estate and construct an inpatient psychiatric hospital; obtaining a CON requires multi-year administrative hearings and can be litigated by incumbents.
• Hospital Joint Ventures: To penetrate markets without building from scratch, Acadia partners with prominent non-profit health systems (e.g., Vanderbilt University Medical Center, Geisinger Health System) to co-own behavioral hospitals. The health system contributes branding and patient referrals from overcrowded emergency departments, while Acadia manages day-to-day operations.

B. Moat Erosion Drivers: The Regulatory and Reputational Death Spiral

Under Rule 07, Acadia’s moat is diagnosed with an active Narrowing trajectory:

• Reputational Degradation Among Referral Networks: Emergency department physicians, social workers, and police departments are the primary conduits for involuntary psychiatric holds. Following widespread media coverage of predatory detention tactics, referral sources have begun diverting patients to county hospitals and non-profit behavioral wards.
• Medicaid Payer Clawbacks & Exclusions: In early 2026, New York State formally banned Medicaid referrals to Acadia’s Pennsylvania facilities. If other major state Medicaid programs follow suit, Acadia’s occupancy rates will collapse.
• Clinical Labor Shortages & Wage Inflation: Inpatient psychiatric facilities require high nurse-to-patient staffing ratios. Severe shortages of psychiatric nurses and behavioral health technicians have forced Acadia to utilize expensive third-party traveling nurse agencies, depressing operating margins by 200–300 bps.

C. Scale Economics Shared (SES) vs Scale Retained

Under Nick Sleep’s framework, Acadia displays zero Scale Economics Shared. The company does not return operational efficiencies to patients, insurers, or taxpayers through lower per-diem rates. Instead, Acadia historically used its scale to maximize lengths of stay and billable ancillary charges, retaining margins until regulatory pushback intervened.

D. Spawner DNA (Mohnish Pabrai Test)

Acadia lacks spawner DNA. Its historical attempt to expand internationally into the United Kingdom via the 2016 acquisition of The Priory Group for £1.3 billion was a catastrophic failure. The UK business was plagued by regulatory investigations and operational losses, forcing Acadia to divest Priory in 2021 at a substantial loss to pay down emergency debt. Acadia remains a single-product roll-up.

---

3. Financial Quality & Balance Sheet Fortress

• Financial Health Classification: Vulnerable
• S&P Credit Rating: BB- (Negative Outlook)
• Total Funded Debt: **$2.41 Billion** ($2,382.1M long-term debt + $32.5M current portion)
• Net Debt: **$2.24 Billion** ($2.41B debt - $171.3M cash)
• Net Debt / Adjusted EBITDA: 3.8x (vs. Gate K3 maximum hurdle of 3.5x)
• Tangible Book Value: ~$450 Million -$500 Million (~$5.00/share after subtracting$1.30B in remaining goodwill)

Historical SEC XBRL Financial Statements & Cash Flow Time Series:

Metric	FY2021	FY2022	FY2023	FY2024	FY2025	CY2026 H1 / TTM
Total Revenue	$2.31B	$2.61B	$2.93B	$3.15B	$3.31B	~$3.40B
Operating Income (EBIT)	$285.4M	$392.1M	$28.4M	$401.5M	-$950.2M	~$160.0M
GAAP Net Income (Loss)	$190.6M	$273.1M	-$21.7M	$255.6M	-$1.10B	~$25.0M
Operating Cash Flow (OCF)	$374.5M	$380.6M	$462.3M	$129.7M	$131.9M	~$340.0M
Capital Expenditures (CapEx)	$244.8M	$296.1M	$424.1M	$690.4M	$571.8M	~$230.0M
Owner Free Cash Flow	$92.1M	$54.8M	$5.9M	-$597.8M	-$471.6M	~$80.0M
Terry Smith FCF/NI Conversion	68.0%	30.9%	N/A	-219.4%	N/A	Variable
Cash & Short-Term Equivalents	$133.8M	$97.6M	$100.1M	$76.3M	$133.2M	$171.3M
Total Funded Debt	$1.48B	$1.36B	$1.34B	$1.88B	$2.47B	$2.41B
Net Funded Debt	$1.34B	$1.27B	$1.24B	$1.80B	$2.34B	$2.24B
Diluted Shares Outstanding	90.8M	91.6M	90.9M	92.1M	90.7M	90.7M
Stockholders’ Equity	$2.72B	$2.98B	$2.95B	$3.08B	$1.95B	$1.94B

flowchart LR
    subgraph SolvencyAudit["Knockout Gate K3 & K4 Solvency Audit"]
        direction TB
        D1["Funded Debt: <b>$2.41B</b><br/>Net Debt: <b>$2.24B</b>"]
        D2["Net Debt / EBITDA: <b>3.8x</b><br/>(Gate Limit: <= 3.5x) -> <b>FAILED</b>"]
        D3["5-Year Owner FCF: <b>-$916.6M</b><br/>(Severe Cash Burn) -> <b>FAILED</b>"]
        D4["Goodwill Impairment: <b>$996.2M</b><br/>(Forensic Red Flag) -> <b>FAILED</b>"]
    end
    D1 & D2 & D3 & D4 --> DISQ["<b>GATE K3 & K4 DISQUALIFIED (AVOID)</b>"]

+==================================================================================================+
|                        THE 4 KNOCKOUT DISQUALIFICATION GATES (PASS / FAIL)                       |
+==================================================================================================+

[PASS] GATE K1: THE CIRCLE OF COMPETENCE & SIMPLICITY GATE (Buffett, Munger, Pabrai, Li Lu)
       - Acadia's core business model is straightforward: providing inpatient and outpatient behavioral
         healthcare services reimbursed via commercial insurers, Medicare, and Medicaid. Unit economics
         are driven by bed count, average daily census (occupancy), and revenue per patient day.
       --> STATUS: PASSED.

[PASS] GATE K2: THE SECTOR & FRAGILITY EXCLUSION SCREEN (Terry Smith)
       - Is the company a commercial bank, life/P&C insurer, real estate developer, unhedged
         commodity extractor, commercial airline, or highly cyclical heavy manufacturer?
       - NO: Operates in healthcare services (SIC 8093: Specialty Outpatient Facilities).
       --> STATUS: PASSED.

[FAIL] GATE K3: THE FINANCIAL DISTRESS & REFINANCING WALL (Graham, Marks, Ackman)
       - Does Net Debt / EBITDA exceed 3.5x during benign economic conditions?
       - YES: Net Debt stands at $2.24 billion against normalized Adjusted EBITDA of ~$590M-$615M,
         yielding a 3.7x-3.8x leverage ratio (and far higher on reported GAAP EBITDA).
       - S&P maintains a BB- rating with Negative Outlook. Annual interest expense exceeds $145M.
       --> STATUS: FAILED -> AUTOMATIC DISQUALIFICATION ("AVOID").

[FAIL] GATE K4: FORENSIC ACCOUNTING & EARNINGS INTEGRITY GATE (Terry Smith, Graham, Munger)
       - Multi-year Owner Free Cash Flow from 2021-2025 totaled -$916.6 million due to aggressive
         facility buildouts ($1.26B capex in 2024-2025 alone).
       - $996.2 million non-cash goodwill impairment in Q4 2025, confirming historical capital misallocation.
       - Active DOJ and SEC investigations into systemic involuntary patient holds and fraudulent billing.
       - $179 million securities class action settlement and surging PLGL liability provisions.
       --> STATUS: FAILED -> CRITICAL FORENSIC RED FLAGS ("AVOID").
+==================================================================================================+

---

4. Capital Allocation & Management Track Record

• ROIC / ROCE Collapse: Historically, Acadia generated modest ROIC of 6%–8%, barely matching its weighted average cost of capital (WACC ~8.5%–9.0%). In FY2025, the $996M impairment pushed reported ROIC deep into negative territory. Even on a normalized through-the-cycle basis, ROIC averages just 3.2%, destroying shareholder value.
• **Buffett $1 Retained Earnings Test**: Failed completely. Over the past decade, retained earnings and massive debt issuances were channeled into greenfield expansions and hospital acquisitions that resulted in nearly$1 billion in asset write-downs and a depressed market capitalization.
• Share Cannibalization & Capital Discipline: Diluted share count has hovered around 90.7M to 92.1M shares. Management has conducted zero meaningful share repurchases, as every dollar of operational cash flow is devoured by debt interest service, growth capex, and legal settlement reserves.
• Executive Compensation Misalignment: CEO Chris Hunter and executive leadership are incentivized primarily through Adjusted EBITDA and top-line bed expansion targets. This compensation architecture directly incentivized local hospital administrators to artificially inflate lengths of stay and admit marginally qualified patients to meet aggressive EBITDA hurdles, directly creating the current regulatory crisis.

---

5. Valuation, Reverse DCF & Margin of Safety

• Current Market Share Price: $29.96
• Probability-Weighted Intrinsic Fair Value: $26.75
• Margin of Safety (MOS): -12.0% (Overvalued Relative to Turnaround Fair Value)
• Klarman Downside Floor Test: Price ($29.96) is **99.7$15.00). FAILED.

Three-Scenario Intrinsic Valuation Triangulation (Rule 05):

1. Bear Case ($15.00 per share - 25% Weight - Klarman Downside Floor):
   • DOJ and SEC investigations culminate in a substantial civil settlement with federal monitors; additional states join New York in restricting Medicaid admissions; patient admission volume softens by 10%; professional liability expenses rise to $80M+/year; adjusted EBITDA drops below$450M.
   • Normalized Owner Free Cash Flow falls to $100M ($1.10 per share). Capitalized at an 8.0x trough workout multiple plus tangible book support yields a downside floor of $15.00 per share.
2. Base Case ($24.50 per share - 50% Weight):
   • Inelastic demand for psychiatric beds stabilizes occupancy at ~82%; management successfully curtails growth capex to ~$230M/year, allowing positive cash generation; legal fallout remains confined to monetary settlements without loss of CMS accreditation; normalized Owner Free Cash Flow stabilizes at ~$200M ($2.20 per share).
   • Capitalized at an 11.0x normalized multiple reflecting high ongoing debt overhead: Intrinsic fair value is $24.50 per share.
3. Bull Case ($43.00 per share - 25% Weight):
   • DOJ/SEC probes conclude with a manageable settlement (<$150M) and no operational disruptions; Medicaid referral partnerships are restored; hospital joint-venture pipeline adds 800+ high-margin beds; adjusted EBITDA rebounds to$700M; normalized Owner Free Cash Flow reaches $300M ($3.30 per share).
   • At a 13.0x multiple: Intrinsic fair value reaches $43.00 per share.

$\text{Probability-Weighted Intrinsic Fair Value} = (0.25 \times \$15.00) + (0.50 \times \$24.50) + (0.25 \times \$43.00) = \$3.75 + \$12.25 + \$10.75 = \mathbf{\$26.75}$ $\text{Margin of Safety} = \frac{\$26.75 - \$29.96}{\$26.75} \times 100 = \mathbf{-12.0\%}$

Reverse DCF Implied Growth Analysis

Under Michael Mauboussin’s reverse DCF model, to justify the current market price of $29.96**, Acadia would need to generate **over$275 million in perpetual annual Owner Free Cash Flow compounding at 8% annually for the next decade while completely paying off its $2.24 billion net debt load.

Given that Acadia generated negative cumulative Owner Free Cash Flow of -$916.6 million over the trailing 5 years, and faces tens of millions in unresolved legal liabilities, Mr. Market is pricing in a flawless, friction-free turnaround with zero margin of safety.

---

6. The 100-Point Master Value Score Breakdown

### Master Value Scorecard (Rule 07)
- **Pillar 1: Business Model Quality & Simplicity**: 13 / 20 pts
  - Simplicity & Predictability (3/5) | Repeat Demand (4/5) | Lynch Archetype (3/5) | Secular Runway (3/5)
- **Pillar 2: Economic Moat Durability & Spawner DNA**: 9 / 25 pts
  - Moat Depth & Source (4/8) | Moat Trend (1/6) | Gross Margin Shield (2/4) | SES Flywheel (1/4) | Spawner DNA (1/3)
- **Pillar 3: Financial Fortress & Solvency**: 3 / 20 pts
  - Leverage & Coverage (0/6) | Working Capital (2/4) | Maturity Ladder (1/3) | Cash Conversion (0/4) | Red Flag Screen (0/3)
- **Pillar 4: Capital Allocation & Management Integrity**: 4 / 15 pts
  - ROIC/ROCE (1/5) | Incremental Returns / $1 Test (1/4) | Buyback Discipline (1/3) | Insider Alignment (1/3)
- **Pillar 5: Valuation, Margin of Safety & Asymmetry**: 2 / 20 pts
  - Margin of Safety (0/8) | Klarman Bear Floor (0/4) | Earnings/FCF Yield (1/3) | Lynch PEG (1/3) | Dhandho Asymmetry (0/2)

- **TOTAL MASTER VALUE SCORE**: **31 / 100** -> **Failing Quality Gate / Avoid**
- **Action Verdict**: **Avoid** (MOS: -12.0%)

---

7. What Would Invalidate the Thesis?

What Would Cause an Upgrade to HOLD or BUY?

1. Global DOJ / SEC Settlement with No Exclusion: Comprehensive civil resolution of federal investigations with total monetary penalties under $200M, full preservation of CMS billing privileges, and zero state-level Medicaid referral bans.
2. Deleveraging Below Gate K3 Limit: Sustained debt reduction using operating cash flow that drives consolidated Net Debt / EBITDA comfortably below 2.5x ($1.5B net debt or lower).
3. Multi-Year Positive Cash Flow Generation: Demonstrating three consecutive years of positive Owner Free Cash Flow exceeding $250M after fully funding all facility maintenance and life-safety capex.
4. Valuation De-Rating Below Bear Floor: Stock declining below the Seth Klarman Bear Floor ($15.00 per share), creating an asymmetric Margin of Safety >= 40% for deep value turnaround allocators.

What Would Accelerate Downside / Insolvency Risk?

1. CMS Provider De-Certification: Federal revocation of Medicare or Medicaid billing eligibility for key regional hospital facilities, immediately terminating >50% of revenue.
2. Criminal Indictments & Treble Damages: Federal prosecutors bringing criminal fraud charges under the False Claims Act regarding fraudulent involuntary detentions, triggering multi-hundred-million-dollar liabilities.
3. Credit Downgrade & Liquidity Lockup: S&P or Moody’s downgrading senior debt deeper into junk territory (B/CCC+), triggering credit agreement covenant breaches and blocking refinancing of upcoming maturities.
4. Widespread Medicaid Program Bans: Additional state Medicaid departments (e.g., Texas, Florida, California) following New York’s precedent by banning referrals to Acadia facilities.